Evidence map›Paper›PMID 38909836›Full record

ArticleArchives of biochemistry and biophysics2024

Interaction of CYP3A4 with the inhibitor cobicistat: Structural and mechanistic insights and comparison with ritonavir.

Irina F Sevrioukova

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Irina F SevrioukovaDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA, 92697-3900, USA. Electronic address: sevrioui@uci.edu.

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
Toxicological importance of CYP3A4 catalysis and inhibitionR01ES025767 · NIEHS · UNIVERSITY OF CALIFORNIA-IRVINE · PI SEVRIOUKOVA, IRINA F · 2016 to 2025
$4.0M
NIEHS NIH HHS R01 ES025767NIGMS NIH HHS P30 GM124169
6 · The paper itself

Abstract

Cobicistat is a derivative of ritonavir marketed as a pharmacoenhancer for anti-HIV therapy. This study investigated the interaction of cobicistat with the target protein, drug-metabolizing cytochrome P450 3A4 (CYP3A4), at the molecular level using spectral, kinetic, functional, and structural approaches. It was found that, similar to ritonavir, cobicistat directly coordinates to the heme via the thiazole nitrogen but its affinity and the binding rate are 2-fold lower: 0.030 μM and 0.72 s

Indexed as

CobicistatCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsRitonavirCatalytic DomainCrystallography, X-RayHumansKineticsProtein BindingCobicistatCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsRitonavirCobicistatCrystal structureCYP3A4Inhibitory complexRitonavir

Identifiers

PMID38909836
PMCPMC11286144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.